Bone Graft and Substitute Market's Potholed Product Landscape A vast range of bone grafts and substitutes is available for clinical use. As per Inkwood Research, the global bone graft and substitute market is projected to register a CAGR of 5.40% during the forecast period, 2023-2032. Yet, effective reconstructive device development is extremely challenging. The translational pathway for novel technologies is slow and only facilitates minor enhancements in established clinical treatments. Safety concerns, high economic requirements, and scalability constitute the major impediments to bone graft product development. Over the years, advancements in technology and biomaterial science have facilitated several bone graft types from different sources, such as synthetic materials (alloplastic graft), human cadavers (allograft), and animals (xenograft). For instance, the development of the synthetic bone graft, Inductigraft™ (AltaPore™ in the United States), built on the pioneering research of the Queen Mary University of London by Dr Karin Hing.
The research encompassed a wide range of academics and scientists across the University and other institutions. Inductigraft™ is acknowledged as an effective autograft with the bigger advantage of not needing additional surgery to harvest the autograft. Consequently, lesser anesthesia and a shorter operation time for the patient. (Source) Accordingly, rigorous research efforts have been centered on developing innovative bone substitutes that offer immediate mechanical support alongside ensuring appropriate graft anchoring. At the same time, out of the innumerable studies associated with bone graft development, only a few have stood the test of time, regulations, and safety. This impediment is accredited to several factors, as found out by various studies undertaken.
The following sections shed light on the same –